Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

Partnerships with Eli Lilly and Novartis have allowed us to tackle challenging problems in drug design, leading to the discovery of new chemical matter.

Video

SC

The Quest to ‘Solve All Diseases’ with AI: Isomorphic Labs’ Max Jaderberg

@ Sequoia Capital

The Quest to ‘Solve All Diseases’ with AI: Isomorphic Labs’ Max Jaderberg

04/29/25

Related Takeaways

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

Our internal drug design projects focus on immunology and oncology, and we've made significant progress using advanced models.

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

At Isomorphic Labs, we collaborate with various companies to generate proprietary data, which has proven to be impactful in drug development.

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

Building a diverse team of experts in AI, chemistry, and biology is essential for questioning traditional approaches and fostering innovation in drug design.

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.

MJ

Max Jaderberg

04/29/25

@ Sequoia Capital

The ambition at Isomorphic Labs is to develop a drug design engine that can continuously adapt and apply to new challenges across different diseases, fundamentally changing drug discovery.

SP

Scott Patterson

07/30/18

@ Y Combinator

At Notable Labs, we focus on personalized drug discovery for blood cancer by testing combinations of approved drugs on patients' actual cells.

LF

Lex Fridman Cast

03/25/25

@ Lex Fridman

Investing in unconventional scientific projects can lead to transformative discoveries, as seen with the potential of lizard venom-derived drugs for treating diseases.

YC

Y Combinator Cast

02/24/15

@ Y Combinator

We have received many applications from hardware and biotech companies, and we are adapting our approach to support their longer growth timelines.

ES

Eric Schmidt

05/16/25

@ TED

The future holds the potential to eradicate diseases, with nonprofits working to identify all human druggable targets to aid the drug industry.